Video Library
Therapeutic Management of Dyslipidaemia
In this video, Prof. Christopher Cannon provides a comprehensive overview of our infographic on the therapeutic management of dyslipidaemia. Dyslipidaemia, a key risk factor for cardiovascular diseases, is conventionally managed through therapies targeting lipoproteins such as LDL, Lp(a), IDL + VLDL through small-molecule therapeutics. Despite their effectiveness, off-target events and poor patient compliance often pose significant challenges. Hence novel therapeutics, such as small interfering RNAs, antisense oligonucleotides, and monoclonal antibodies have been developed. These advancements highlight a significant step forward in the management of dyslipidaemia. Prof. Cannon emphasizes these main points in the video, aiming to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.
Prof. Christopher Cannon
First published: August 1, 2024
Running time: 35 minutes, 49 seconds
00.16 Lp(a) structure and metabolism
01.51 Elevated Lp(a) prevalence and risk of cardiovascular diseases
02.38 Factors influencing Lp(a) level
03.35 Physiological functions of Lp(a)
04.12 Atherogenicity of Lp(a)
04.56 Clinical implication of Lp(a) elevation
05.25 Genetic variants associated with increased Lp(a) concentrations
05.44 Association between high Lp(a) level and risk of various cardiovascular diseases
07.43 Clinical implication of Lp(a) elevation at low LDL-C
08.47 Lp(a) categories increases absolute baseline risk of traditional risk factors
09.40 Is reducing Lp(a) physiologically safe?
10.34 Strategies to lower Lp(a) level
11.57 Future directions in Lp(a) research
12.37 Summary
Video Library
Lp(a):What is it and its role in atherosclerosis
In this video, Prof. Lale Tokgozoglu of Hacettepe University, former president of the European Atherosclerosis Society, discusses the structure, function, and genetics of Lp(a) and highlights the clinical implications of elevated Lp(a) levels. Using evidence from contemporary clinical studies, Prof. Tokgozoglu shares insights into approaches for lowering Lp(a) levels. Finally, challenges in the comprehensive understanding of the physiological and clinical implications of Lp(a) are discussed. Learning outcome – High levels of lipoprotein(a) increase the chances of experiencing heart attack, stroke, and aortic stenosis.
Prof. S. Lale Tokgözoğlu
First published: March 11, 2024
Video Library
Lipid measurements in the management of cardiovascular diseases
In this video, Prof. Stephen Nicholls provides a comprehensive overview of our infographic on lipid measurements and their clinical implications, serving as a helpful resource for healthcare professionals involved in managing cardiovascular disease. Covering atherogenic dyslipidemia, lipid profile components, advanced tests, and genetic considerations, Prof. Nicholls emphasizes individualized approaches to interpreting lipid parameters based on patient demographics and risk levels. This aims to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.
First published: March 6, 2024
Video Library
Peer-to-Peer Discussion: Novel lipid-lowering therapies
Editorial Panel Member Prof. Christopher Cannon interviews Prof. Kausik Ray, (President European Atherosclerosis Society and Professor of Public Health and Honorary Consultant Cardiologist, Imperial College London) on the program to roll out the latest PCSK9 inhibitor Inclisiran, first-in-class siRNA to lower cholesterol in the United Kingdom.
To note, the US Food and Drug Administration (FDA) recently approved Inclisiran as an add-on therapy to lower cholesterol among certain high-risk adults on maximally tolerated statin therapy.
Prof. Christopher Cannon, Prof. Kausik Ray
First published: January 10, 2022